Our findings have important clinical implications: Knowledge of future tau spread can be critical for predicting clinical disease progression, since the level of tau is the strongest predictor of cognitive impairment and cognitive decline in AD36,37. The gene discussed is MAPT; the disease is Cognitive impairment.